Evolving therapies in the treatment of hepatocellular carcinoma

Hans Christian Spangenberg, Robert Thimme, Hubert E BlumDepartment of Medicine II, University of Freiburg, D-79106 Freiburg, GermanyAbstract: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide. The major etiologies and risk factors for HCC development are well define...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hans Christian Spangenberg, Robert Thimme, Hubert E Blum
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/f20bb1efe6c84d029414f049c8bd3235
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f20bb1efe6c84d029414f049c8bd3235
record_format	dspace
spelling	oai:doaj.org-article:f20bb1efe6c84d029414f049c8bd32352021-12-02T08:40:35ZEvolving therapies in the treatment of hepatocellular carcinoma1177-5491https://doaj.org/article/f20bb1efe6c84d029414f049c8bd32352008-09-01T00:00:00Zhttps://www.dovepress.com/evolving-therapies-in-the-treatment-of-hepatocellular-carcinoma-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Hans Christian Spangenberg, Robert Thimme, Hubert E BlumDepartment of Medicine II, University of Freiburg, D-79106 Freiburg, GermanyAbstract: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide. The major etiologies and risk factors for HCC development are well defined and some of the steps involved in hepatocarcinogenesis have been elucidated in recent years. Therapeutic options that can be applied in curative or palliative intention are available and are dependent on the HCC stage. The therapeutic options fall into five main categories: (1) surgical interventions, including tumor resection and liver transplantation, (2) percutaneous interventions, including ethanol injection and radiofrequency thermal ablation, (3) transarterial interventions, including embolization and chemoembolization, (4) radiation therapy, and (5) drugs as well as gene and immune therapies. Until recently, no therapy existed for patients with advanced HCC. In 2007 a multikinase inhibitor (sorafenib) showed for the first time a significant increase in overall survival in patients with advanced HCC. Furthermore, several other agents that target different factors of hepatocarcinogenesis (eg, epidermal growth factor, insulin-like growth factors, hepatocyte growth factor, vascular endothelial growth factor, fibroblast growth factor, platelet-derived growth factor, and the transforming growth factors-α and -β), have emerged and been tested in clinical trials. This review gives an overview of the current therapeutic strategies and their clinical impact.Keywords: hepatocellular carcinoma, targeted therapy, sorafenib, antiangiogenesisHans Christian SpangenbergRobert ThimmeHubert E BlumDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 3, Pp 453-462 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Hans Christian Spangenberg Robert Thimme Hubert E Blum Evolving therapies in the treatment of hepatocellular carcinoma
description	Hans Christian Spangenberg, Robert Thimme, Hubert E BlumDepartment of Medicine II, University of Freiburg, D-79106 Freiburg, GermanyAbstract: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide. The major etiologies and risk factors for HCC development are well defined and some of the steps involved in hepatocarcinogenesis have been elucidated in recent years. Therapeutic options that can be applied in curative or palliative intention are available and are dependent on the HCC stage. The therapeutic options fall into five main categories: (1) surgical interventions, including tumor resection and liver transplantation, (2) percutaneous interventions, including ethanol injection and radiofrequency thermal ablation, (3) transarterial interventions, including embolization and chemoembolization, (4) radiation therapy, and (5) drugs as well as gene and immune therapies. Until recently, no therapy existed for patients with advanced HCC. In 2007 a multikinase inhibitor (sorafenib) showed for the first time a significant increase in overall survival in patients with advanced HCC. Furthermore, several other agents that target different factors of hepatocarcinogenesis (eg, epidermal growth factor, insulin-like growth factors, hepatocyte growth factor, vascular endothelial growth factor, fibroblast growth factor, platelet-derived growth factor, and the transforming growth factors-α and -β), have emerged and been tested in clinical trials. This review gives an overview of the current therapeutic strategies and their clinical impact.Keywords: hepatocellular carcinoma, targeted therapy, sorafenib, antiangiogenesis
format	article
author	Hans Christian Spangenberg Robert Thimme Hubert E Blum
author_facet	Hans Christian Spangenberg Robert Thimme Hubert E Blum
author_sort	Hans Christian Spangenberg
title	Evolving therapies in the treatment of hepatocellular carcinoma
title_short	Evolving therapies in the treatment of hepatocellular carcinoma
title_full	Evolving therapies in the treatment of hepatocellular carcinoma
title_fullStr	Evolving therapies in the treatment of hepatocellular carcinoma
title_full_unstemmed	Evolving therapies in the treatment of hepatocellular carcinoma
title_sort	evolving therapies in the treatment of hepatocellular carcinoma
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/f20bb1efe6c84d029414f049c8bd3235
work_keys_str_mv	AT hanschristianspangenberg evolvingtherapiesinthetreatmentofhepatocellularcarcinoma AT robertthimme evolvingtherapiesinthetreatmentofhepatocellularcarcinoma AT huberteblum evolvingtherapiesinthetreatmentofhepatocellularcarcinoma
_version_	1718398440690417664

Evolving therapies in the treatment of hepatocellular carcinoma

Ejemplares similares